Validation of biomarkers and immunotherapy in head and neck squamous cell carcinoma using bioinformatics and Mendelian randomization

References

• Rampinelli V, Gennarini F, Borsetto D, et al. Head and neck squamous cell carcinoma in HIV patients. Curr Opin Otolaryngol Head Neck Surg. 2023;31(2):78–82. doi: 10.1097/MOO.0000000000000868.
   PubMed Web of Science ®Google Scholar
• Romanowska K, Sobecka A, Rawłuszko-Wieczorek AA, et al. Head and neck squamous cell carcinoma: epigenetic landscape. Diagnostics (Basel). 2020;11(1):34. doi: 10.3390/diagnostics11010034.
   PubMedGoogle Scholar
• Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–1160. doi: 10.1126/science.1208130.
   PubMed Web of Science ®Google Scholar
• Nair S, Bonner JA, Bredel M. EGFR mutations in head and neck squamous cell carcinoma. Int J Mol Sci. 2022;23(7):3818.
   Web of Science ®Google Scholar
• Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. doi: 10.1038/s41572-020-00224-3.
   PubMed Web of Science ®Google Scholar
• Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018;52(Pt 2):228–240. doi: 10.1016/j.semcancer.2018.01.008.
   PubMed Web of Science ®Google Scholar
• Mei Z, Huang J, Qiao B, et al. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 2020;12(1):16. doi: 10.1038/s41368-020-0084-8.
   PubMed Web of Science ®Google Scholar
• Jo DH, Kim JH, Kim JH. Tumor environment of retinoblastoma, intraocular cancer. [journal article]. Adv Exp Med Biol. 2020;1296:349–358. doi: 10.1007/978-3-030-59038-3_21.
   PubMed Web of Science ®Google Scholar
• Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. [journal article; research support, Non-U.S. Gov’t; review]. Mol Cancer. 2021;20(1):28. doi: 10.1186/s12943-021-01316-8.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. [historical article; journal article; research support, Non-U.S. Gov’t; review]. Cell Mol Immunol. 2020;17(8):807–821. doi: 10.1038/s41423-020-0488-6.
   PubMed Web of Science ®Google Scholar
• Ebeling PR, Nguyen HH, Aleksova J, et al. Secondary osteoporosis. Endocr Rev. 2022;43(2):240–313. doi: 10.1210/endrev/bnab028.
   PubMed Web of Science ®Google Scholar
• Martel D, Monga A, Chang G. Osteoporosis imaging. Radiol Clin North Am. 2022;60(4):537–545. doi: 10.1016/j.rcl.2022.02.003.
   PubMed Web of Science ®Google Scholar
• Wu Z, Liu P, Huang B, et al. A novel alzheimer’s disease prognostic signature: identification and analysis of glutamine metabolism genes in immunogenicity and immunotherapy efficacy. Sci Rep. 2023;13(1):6895. doi: 10.1038/s41598-023-33277-x.
   PubMed Web of Science ®Google Scholar
• Ho AL, Brana I, Haddad R, et al. Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol. 2021;39(17):1856–1864. doi: 10.1200/JCO.20.02903.
   PubMed Web of Science ®Google Scholar
• Moon DH, Sher DJ. Oligometastasis in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2022;114(4):803–811. doi: 10.1016/j.ijrobp.2022.06.086.
   PubMed Web of Science ®Google Scholar
• Guo Z, Li K, Liu P, et al. Targeted therapy for head and neck squamous cell carcinoma microenvironment. Front Med (Lausanne). 2023;10:1257898. doi: 10.3389/fmed.2023.1257898.
   PubMed Web of Science ®Google Scholar
• Koh J, Walsh P, D'Costa I, et al. Head and neck squamous cell carcinoma survivorship care. Aust J Gen Pract. 2019;48(12):846–848. doi: 10.31128/AJGP-08-19-5032.
   PubMed Web of Science ®Google Scholar
• Chaves P, Garrido M, Oliver J, et al. Preclinical models in head and neck squamous cell carcinoma. Br J Cancer. 2023;128(10):1819–1827. doi: 10.1038/s41416-023-02186-1.
   PubMed Web of Science ®Google Scholar
• Garcia-Mayea Y, Benítez-Álvarez L, Sánchez-García A, et al. Transcriptomic and proteomic profiles for elucidating cisplatin resistance in head-and-neck squamous cell carcinoma. Cancers (Basel). 2022;14(22):5511. doi: 10.3390/cancers14225511.
   PubMed Web of Science ®Google Scholar
• Khera N, Rajkumar AS, Abdulkader MAK, et al. Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells. Mol Cancer. 2023;22(1):146. doi: 10.1186/s12943-023-01846-3.
   PubMed Web of Science ®Google Scholar
• Wu X, Xiao Y, Zhou S, et al. Transcriptomic landscape of gene expression profiles and pathways in Juvenile-Onset recurrent respiratory papillomatosis tumor tissues and human papillomavirus 6 and 11 E6- and E7-Overexpressing head and neck squamous cell carcinoma cell lines. J Virol. 2022;96(2):e134221. doi: 10.1128/JVI.01342-21.
   Web of Science ®Google Scholar
• Crist M, Yaniv B, Palackdharry S, et al. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition. J Immunother Cancer. 2022;10(11):e005632. doi: 10.1136/jitc-2022-005632.
   PubMed Web of Science ®Google Scholar
• Allen JL, Hames RA, Mastroianni NM, et al. Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor andecaliximab as an anti-invasive therapeutic in head and neck squamous cell carcinoma. Oral Oncol. 2022;132:106008. doi: 10.1016/j.oraloncology.2022.106008.
   PubMedGoogle Scholar
• Ling Z, Li W, Hu J, et al. Targeting CCL2-CCR4 axis suppress cell migration of head and neck squamous cell carcinoma. Cell Death Dis. 2022;13(2):158. doi: 10.1038/s41419-022-04610-5.
   PubMed Web of Science ®Google Scholar
• Jiang BC, Ding TY, Guo CY, et al. NFAT1 orchestrates spinal microglial transcription and promotes microglial proliferation via c-MYC contributing to nerve Injury-Induced neuropathic pain. Adv Sci (Weinh). 2022;9(27):e2201300.
   PubMedGoogle Scholar
• Deng J, Parthasarathy V, Marani M, et al. Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis. Front Med (Lausanne). 2022;9:1022889. doi: 10.3389/fmed.2022.1022889.
   PubMed Web of Science ®Google Scholar
• Cao L, Malon JT. Anti-nociceptive role of CXCL1 in a murine model of peripheral nerve injury-induced neuropathic pain. Neuroscience. 2018;372:225–236. doi: 10.1016/j.neuroscience.2017.12.048.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Zhang X, Wei W, et al. Lycorine improves peripheral nerve function by promoting schwann cell autophagy via AMPK pathway activation and MMP9 downregulation in diabetic peripheral neuropathy. Pharmacol Res. 2022;175:105985. doi: 10.1016/j.phrs.2021.105985.
   PubMed Web of Science ®Google Scholar
• Awad-Igbaria Y, Ferreira N, Keadan A, et al. HBO treatment enhances motor function and modulates pain development after sciatic nerve injury via protection the mitochondrial function. J Transl Med. 2023;21(1):545. doi: 10.1186/s12967-023-04414-x.
   PubMed Web of Science ®Google Scholar
• Du S, Wu S, Feng X, et al. A nerve injury-specific long noncoding RNA promotes neuropathic pain by increasing Ccl2 expression. J Clin Invest. 2022;132(13):e153563.
   Web of Science ®Google Scholar
• Chen J, Lu T, Zhong F, et al. A signature of N(6)-methyladenosine regulator-related genes predicts prognoses and immune responses for head and neck squamous cell carcinoma. Front Immunol. 2022;13:809872. doi: 10.3389/fimmu.2022.809872.
   PubMed Web of Science ®Google Scholar
• Oliva M, Spreafico A, Taberna M, et al. Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol. 2019;30(1):57–67. doi: 10.1093/annonc/mdy507.
   PubMed Web of Science ®Google Scholar
• Zamani R, Rezaei N. Immune-scoring in head and neck squamous cell carcinoma: a scoping review. Expert Rev Clin Immunol. 2023;1–9. doi: 10.1080/1744666X.2023.2262140.
   PubMed Web of Science ®Google Scholar
• Veigas F, Mahmoud YD, Merlo J, et al. Immune checkpoints pathways in head and neck squamous cell carcinoma. Cancers (Basel). 2021;13(5):1018. doi: 10.3390/cancers13051018.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li ZY, Zhou GQ, et al. An immune-related gene prognostic index for head and neck squamous cell carcinoma. Clin Cancer Res. 2021;27(1):330–341. doi: 10.1158/1078-0432.CCR-20-2166.
   PubMed Web of Science ®Google Scholar
• Wu ZX, Huang X, Cai MJ, et al. Development and validation of a prognostic index based on genes participating in autophagy in patients with lung adenocarcinoma. Front Oncol. 2021;11:799759. doi: 10.3389/fonc.2021.799759.
   PubMedGoogle Scholar
• Li Y, Bi J, Pi G, et al. Exploration of prognostic biomarkers in head and neck squamous cell carcinoma microenvironment from TCGA database. Ann Transl Med. 2023;11(4):163–163. doi: 10.21037/atm-22-6481.
   PubMedGoogle Scholar